
As of March 25, 2025

Company Overview

1

Name	SymBio Pharmaceuticals Limited
Address	Toranomon Towers Office, 7th floor, 4-1-28 Toranomon, Minato-ku, Tokyo 105-0001, Japan Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 For Inquiry about brincidofovir: +81-3-6684-6663
URL	https://www.symbiopharma.com
Established	March 25, 2005
Capital stock	18,336,841 thousands of yen (As of the end of December 2024)
Board of Directors	Fuminori Yoshida Representative Director
	Shigetoshi Matsumoto Board Director <outside></outside>
	Bruce David Cheson Board Director <outside></outside>
	Eiji Ebinuma Board Director <outside></outside>
	Toshio Imabeppu Board Director <outside></outside>
	George Morstyn Board Director <outside></outside>
	Ralph Smalling Board Director <outside></outside>
	Kiyoshi Watanabe Board Director, Full-Time Audit & Supervisory Committee Member <outside></outside>
	Yasuhiro Tamo Board Director, Audit & Supervisory Committee Member <outside></outside>
	Koichi Shimomura Board Director, Audit & Supervisory Committee Member <outside></outside>
Corporate Officers	Fuminori Yoshida President and Chief Executive Officer
	Masaru Taguchi Corporate Vice President and Chief Operation Officer
	Takaaki Fukushima Executive Corporate Officer and Chief Financial Officer
	Paul Marston Corporate Officer and General Counsel
	Koji Fukushima Corporate Officer and Deputy Chief Medical Officer
	Masatoshi Hazama Corporate Officer and Chief Scientific Officer
Subsidiary	SymBio Pharma USA, Inc. Durham, North Carolina, USA



Tokyo Metro Ginza Line/Namboku Line: 7 min walk from Tameike-sanno station

Tokyo Metro Ginza Line: 10 min walk from Toranomon station

Mar. 2005	SymBio Pharmaceuticals Limited established at Nishi-Shimbashi, Minato-ku, Tokyo
Jul. 2005	Head office relocates to Shimbashi, Minato-ku, Tokyo
Dec. 2005	License Agreement finalized with Astellas Pharma GmbH for SyB L-0501 (bendamustine) development & commercialization rights in Japan
Mar. 2006	Manufacturer's License (packaging, labeling and storage) obtained from Tokyo Metropolitan Government
Mar. 2007	License Agreement finalized with Astellas Deutschland GmbH for SyB L-0501 (bendamustine) development & commercialization rights in China (HK), Taiwan, Korea and Singapore
Aug. 2008	License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Japan
Mar. 2009	SymBio Pharmaceuticals concludes Sublicense Agreement with Cephalon, Inc. for development and commercialization rights of bendamustine hydrochloride in China (HK)
May. 2009	License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Korea and Singapore
Oct. 2010	SymBio Pharmaceuticals announces NDA Approval of TREAKISYM® (bendamustine) in Japan
Dec. 2010	SymBio Pharmaceuticals launches TREAKISYM® in Japan
Jul. 2011	Onconova and SymBio Pharmaceuticals complete License Agreement for SyB L-1101/SyB C-1101 (rigosertib, a PhaseIII stage multi-kinase inhibitor for Myelodysplastic Syndromes)
Oct. 2011	Listed on Osaka Securities Exchange JASDAQ Growth Market
Nov. 2014	Head Office relocates to Toranomon, Minato-ku, Tokyo
May. 2016	SymBio Pharma USA, Inc. established at Menlo Park, California, USA
Aug. 2016	SymBio Pharmaceuticals announces the NDA approval of TREAKISYM®(bendamustine) for the additional indication of chronic lymphocytic leukemia in Japan
Dec. 2016	SymBio Pharmaceuticals announces the NDA approval of TREAKISYM® (bendamustine) for the additional indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma in Japan
Sep. 2017	Eagle Pharmaceuticals (NASDAQ: EGRX) and SymBio Pharmaceuticals completed License Agreement for bendamustine liquid formulations (RTD Injection and RI Injection) development & commercialization rights in Japan * RTD: Ready-to-dilute, RI: Rapid Infusion
Jul. 2018	TREAKISYM® (bendamustine) has been newly included as a standard-of-care option in the Guidelines for Tumors of Hematopoietic and Lymphoid Tissues 2018
Sep. 2019	SymBio Pharmaceuticals obtained from Chimerix (NASDAQ:CMRX) the exclusive worldwide rights to develop, manufacture, and commercialize brincidofovir (BCV) in all human indications, excluding the prevention and treatment of smallpox
Sep. 2020	SymBio Pharmaceuticals receives approval of TREAKISYM® Ready-To-Dilute (RTD) formulation
Dec. 2020	Commencement of in house sales of the anti cancer agent TREAKISYM®

History

- Market Launch of TREAKISYM® Ready To Dilute (RTD) Formulation Jan. 2021
- Mar. 2021 SymBio Pharmaceuticals receives approval of TREAKISYM® (bendamustine) in combination with rituximab, and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B cell lymphoma
- Apr. 2021 SymBio Pharmaceuticals receives approval of TREAKISYM® Ready To Dilute (RTD) Formulation in combination with rituximab, and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B cell lymphoma
- Feb. 2022 SymBio Pharmaceuticals receives approval of 10-minute Rapid Infusion (RI) administration of the TREAKISYM® Liquid Formulation
- Dec. 2023 Head office relocates within Toranomon, Minato-ku, Tokyo



Organization Chart

Delivering hope to patients in need •••• SymBio

As of May 7, 2025

